Back to Search
Start Over
Myocardial MMP-2 contributes to SERCA2a proteolysis during cardiac ischaemia-reperfusion injury.
- Source :
-
Cardiovascular research [Cardiovasc Res] 2020 Apr 01; Vol. 116 (5), pp. 1021-1031. - Publication Year :
- 2020
-
Abstract
- Aims: Matrix metalloproteinase-2 (MMP-2) is a zinc-dependent protease which contributes to cardiac contractile dysfunction when activated during myocardial ischaemia-reperfusion (IR) injury. MMP-2 is localized to several subcellular sites inside cardiac myocytes; however, its role in the sarcoplasmic reticulum (SR) is unknown. The Ca2+ ATPase SERCA2a, which pumps cytosolic Ca2+ into the SR to facilitate muscle relaxation, is degraded in cardiac IR injury; however, the protease responsible for this is unclear. We hypothesized that MMP-2 contributes to cardiac contractile dysfunction by proteolyzing SERCA2a, thereby impairing its activity in IR injury.<br />Methods and Results: Isolated rat hearts were subjected to IR injury in the presence or absence of the selective MMP inhibitor ARP-100, or perfused aerobically as a control. Inhibition of MMP activity with ARP-100 significantly improved the recovery of cardiac mechanical function and prevented the increase of a 70 kDa SERCA2a degradation fragment following IR injury, although 110 kDa SERCA2a and phospholamban levels appeared unchanged. Electrophoresis of IR heart samples followed by LC-MS/MS confirmed the presence of a SERCA2a fragment of ∼70 kDa. MMP-2 activity co-purified with SR-enriched microsomes prepared from the isolated rat hearts. Endogenous SERCA2a in SR-enriched microsomes was proteolyzed to ∼70 kDa products when incubated in vitro with exogenous MMP-2. MMP-2 also cleaved purified porcine SERCA2a in vitro. SERCA activity in SR-enriched microsomes was decreased by IR injury; however, this was not prevented with ARP-100.<br />Conclusion: This study shows that MMP-2 activity is found in SR-enriched microsomes from heart muscle and that SERCA2a is proteolyzed by MMP-2. The cardioprotective actions of MMP inhibition in myocardial IR injury may include the prevention of SERCA2a degradation.<br /> (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)
- Subjects :
- Animals
Calcium-Binding Proteins metabolism
Disease Models, Animal
Hydroxamic Acids pharmacology
Isolated Heart Preparation
Male
Matrix Metalloproteinase Inhibitors pharmacology
Myocardial Reperfusion Injury pathology
Myocardial Reperfusion Injury physiopathology
Myocardial Reperfusion Injury prevention & control
Myocardium pathology
Proteolysis
Rats, Sprague-Dawley
Sarcoplasmic Reticulum drug effects
Sarcoplasmic Reticulum pathology
Sulfones pharmacology
Matrix Metalloproteinase 2 metabolism
Myocardial Contraction drug effects
Myocardial Reperfusion Injury enzymology
Myocardium enzymology
Sarcoplasmic Reticulum enzymology
Sarcoplasmic Reticulum Calcium-Transporting ATPases metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1755-3245
- Volume :
- 116
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Cardiovascular research
- Publication Type :
- Academic Journal
- Accession number :
- 31373602
- Full Text :
- https://doi.org/10.1093/cvr/cvz207